National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
Contains
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

rituximab  Patient Information
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:C2B8 Monoclonal Antibody
IDEC-C2B8 monoclonal antibody
US brand name:Rituxan
Foreign brand name:Mabthera
Abbreviation:MOAB IDEC-C2B8
Code names:IDEC-102
IDEC-C2B8


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov